Adenosine
Adenosine · Sleep Pressure / Process S
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
8 human trials, about 300 studies, Foundational neuroscience; human PET/EEG studies in the low hundreds. The written rationale for this grade is still being prepared.
- FDA
- IV adenosine approved (Adenocard, 1989) for PSVT, not for sleep; no sleep indication exists
- WADA
- Adenosine not listed/not prohibited; caffeine (its antagonist) is on the WADA Monitoring Program in-competition, not banned
Reference only. Not medical advice.
What can go wrong
Adenosine is not a consumer sleep supplement, and no oral or sublingual product meaningfully raises brain adenosine: it is destroyed in seconds by adenosine deaminase and does not cross the blood-brain barrier. IV adenosine (Adenocard, Adenoscan) is a prescription drug; in a 20 November 2013 safety communication the FDA warned of rare heart-attack and death risk with the adenosine and regadenoson cardiac stress agents, and the drug can provoke severe bradycardia, asystole and bronchospasm. These are clinical-grade cardiac effects with nothing to do with self-managed sleep. Caffeine timing advice is general-interest, not medical guidance. Persistent insomnia, excessive daytime sleepiness, suspected sleep apnea, or heavy reliance on caffeine to function should be evaluated by a licensed sleep physician rather than self-treated.
Adenosine is the leading molecular candidate for Process S, the homeostatic arm of Alexander Borbely's 1982 two-process model of sleep regulation. As neurons consume energy across the waking day, extracellular adenosine accumulates in specific brain regions and is associated with rising sleep pressure; during sleep it is cleared and pressure falls. The animal evidence came from Porkka-Heiskanen and colleagues (Science, 1997), who showed extracellular adenosine in the cat basal forebrain rises during prolonged waking and that blocking its transport induces sleep. Human evidence is direct: Elmenhorst et al. (2007) used [18F]CPFPX PET to show that 24 hours of sleep deprivation upregulates A1 adenosine receptor availability, peaking in the orbitofrontal cortex, and a 2017 follow-up found recovery sleep restores it. Caffeine, a roughly equipotent A1 and A2A antagonist, is associated with wakefulness; mouse knockout work (Huang et al., 2005) shows the arousal effect requires A2A receptors. The picture is not settled: a 2018 meta-analysis confirmed a large basal-forebrain rise (about 75 percent) but found the cortical signal rests on only two studies, and a 2020 Science study traced the source to glutamatergic, not cholinergic, neurons.
The molecule that tracks how long you have been awake, and the one caffeine blocks to hide the bill.
What it is invoked to explain
Claims this idea is used to support. Whether it supports them is the rest of the entry.
What people get wrong
Often saidCaffeine removes or flushes out adenosine, giving you energy
ActuallyCaffeine does not remove adenosine; it competitively blocks A1 and A2A receptors so accumulated adenosine cannot signal. Sleep pressure is still building underneath, which is associated with the alertness drop when caffeine clears (Reichert et al., 2022).
Often saidAdenosine supplements or sublingual adenosine improve sleep
ActuallyThere is no clinical evidence for this. Circulating adenosine has a half-life near 10 seconds and does not cross the blood-brain barrier, so oral or sublingual dosing cannot raise the brain adenosine associated with sleep pressure.
Often saidAdenosine is definitively THE single molecule that causes sleep
ActuallyIt is the leading candidate for Process S and is widely accepted as sleep-regulatory, but its sufficiency is debated. ATP, P2X7-mediated cytokines and BDNF are co-implicated, the cellular source was revised to glutamatergic neurons in 2020, and the cortical microdialysis evidence rests on only 2 studies (Leenaars et al., 2018; Peng et al., 2020; Reichert et al., 2022).
Often saidWaiting 90 minutes to drink your morning coffee is scientifically proven to boost energy
ActuallyThis advice, popularized by neuroscientist Andrew Huberman, is a plausible extrapolation, not a directly proven protocol. It rests on the cortisol-awakening-response rhythm and on letting adenosine rise so caffeine has more to block, but no published randomized trial has compared delayed versus immediate morning caffeine for next-day alertness, and some clinicians dispute the underlying adenosine-timing premise (Jackson Health System commentary).
Who profits, and who pushes back
Hans-Peter Landolt
Leading academic advocate for adenosine's central role in sleep homeostasis and for ADORA2A-based caffeine sensitivity. Academic, not a product seller; specific industry funding for this topic not confirmed in this session, so labeled unclear.
Coffee and Health (ISIC) information network
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
The Institute for Scientific Information on Coffee, funded by coffee companies, promotes the adenosine-caffeine mechanism narrative; positions stated are that body's framing of the science, not Enel-asserted fact.
Popular sleep-optimization media
Sleep Foundation and similar outlets popularize the coffee-nap and caffeine-timing concepts; many carry affiliate mattress and supplement relationships, so incentivization is mixed.
Carolin Reichert, Tom Deboer and Hans-Peter Landolt
Whether adenosine alone can be responsible for long-term sleep-wake regulation has been questioned, because extracellular adenosine is rapidly metabolized and removed; additional activity-dependent signals such as ATP and BDNF are implicated.
Janneke (C.H.C.) Leenaars et al.
Cortex dialysate adenosine concentrations during sleep deprivation were so far only reported by 2 publications; the increase in adenosine during sleep deprivation might be specific to the basal forebrain.
Jackson Health System (clinical commentary)
There are no definitive studies proving a single optimal post-wake time that is best for everyone; the science around the exact timing is incomplete.
Where the research comes from
Most of the published research on this comes from one place. 50% of it is from Europe. Findings that no unrelated group has reproduced are weaker than the study count makes them look.
| Place | Share of published research |
|---|---|
| Europe | 50% |
| USA | 35% |
| Other | 15% |
Research published from: Switzerland / Germany / USA.
How we got here
Adenosine the molecule is a 20th-century discovery with no traditional or pre-modern use, because it cannot be eaten, brewed, or applied to any effect: it is an intracellular metabolite with a half-life of seconds. Alan N. Drury and Albert Szent-Gyorgyi first described its physiological action at Cambridge in 1929, in the heart, not the brain. Its role in sleep was not proposed until the late 20th century and not directly demonstrated until Porkka-Heiskanen and colleagues in 1997. What humans exploited for millennia was the adenosine SYSTEM, through its antagonist caffeine. Tea from Camellia sinensis enters Chinese tradition by legend with the emperor Shennong (around 2700 BCE) and was adopted by Chan and other Buddhist monks to sustain alertness during long meditation. Coffee emerged from the Ethiopian highlands and was formalized as a beverage by Sufi communities in 15th-century Yemen, who drank qahwa to stay awake for night-long zikr devotions; from Yemen it spread through the Ottoman, Safavid and Mughal worlds. Peoples across the Americas, Africa and Asia independently used caffeine-bearing plants: guarana and yerba mate (Guarani and other South American peoples), cacao (Mesoamerica), cola nut (West Africa), and guayusa (Amazonian Kichwa). None named adenosine; all were, in effect, manipulating it.
- c. 2700 BCE (legend)Tea attributed to emperor Shennong in China; later used by Buddhist monks for wakefulness
- 15th centurySufi communities in Yemen drink qahwa (coffee) to stay awake for night devotions
- 1929Drury and Szent-Gyorgyi describe adenosine's action on the mammalian heart (Cambridge)
- 1982Borbely formalizes the two-process model (Human Neurobiology); Process S is the homeostatic arm
- 1989FDA approves IV adenosine (Adenocard, 30 Oct) for paroxysmal supraventricular tachycardia
- 1997Porkka-Heiskanen et al. (Science) show basal-forebrain adenosine mediates sleepiness from prolonged waking
- 2005Huang et al. (Nature Neuroscience): caffeine's arousal effect requires A2A, not A1, receptors
- 2007Elmenhorst et al. (J Neurosci): PET shows 24h sleep deprivation upregulates human A1 receptors, peaking in orbitofrontal cortex
- 2008FDA approves regadenoson (Lexiscan), an A2A agonist, for cardiac stress imaging
- 2013Drake et al. (JCSM): 400 mg caffeine taken 6h before bed measurably disrupts sleep
- 2017Elmenhorst et al. (PNAS): recovery sleep restores elevated A1 receptor availability
- 2018Leenaars et al. meta-analysis: ~75% (74.7%) basal-forebrain adenosine rise; cortical data from only 2 studies
- 2020Peng et al. (Science): basal-forebrain glutamatergic, not cholinergic, neurons drive the adenosine rise (GRAB sensor)
- 2022Reichert, Deboer and Landolt publish state-of-science review questioning adenosine's sole sufficiency
At a glance
- What it is
- An endogenous purine nucleoside that accumulates with waking and signals sleep pressure
- Process
- The homeostatic Process S of the two-process model
- How caffeine works
- Competitive antagonist at A1 and A2A adenosine receptors
- Why supplements fail
- IV half-life near 10 seconds; does not cross the blood-brain barrier
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Adenosine. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
Adenosine accumulates in cat basal forebrain during prolonged waking and mediates sleepiness; blocking its transport induces sleep
Process S is the homeostatic, waking-dependent arm of the two-process model; declines exponentially in sleep
Borbely, two-process model, Beginnings and outlook (J Sleep Res 2022 reappraisal of the 1982 model)
Caffeine-induced wakefulness requires A2A, not A1, adenosine receptors (knockout mice)
24 h sleep deprivation upregulates human A1 receptor binding region-specifically, max +15.3% in orbitofrontal cortex (12 deprived + 10 controls)
Recovery sleep after extended wakefulness restores elevated A1 adenosine receptor availability
Meta-analysis (8 papers): basal-forebrain adenosine rises 74.7% (95% CI 54.1-95.3) during sleep deprivation; cortical data from only 2 publications, so region-specificity is open
Basal-forebrain glutamatergic (not cholinergic) neurons drive the activity-dependent extracellular adenosine rise; demonstrated with a GRAB adenosine sensor
Adenosine is widely accepted as sleep-regulatory but its sole sufficiency is questioned because it is rapidly metabolized; ATP and BDNF co-implicated
Reichert, Deboer and Landolt, Journal of Sleep Research (PMC)
ADORA2A genotype (rs5751876, 1976C>T) contributes to individual caffeine sensitivity and EEG/SWA responses after sleep deprivation
Retey et al., Clinical Pharmacology and Therapeutics; Landolt program (Genes review reprint)
400 mg caffeine taken 0, 3, or even 6 h before bed significantly disrupts sleep relative to placebo
FDA warns of rare but serious heart-attack and death risk with adenosine (Adenoscan) and regadenoson (Lexiscan) cardiac stress agents (20 Nov 2013)
The viral 90-minute morning-coffee-delay rule has no definitive supporting study; timing science is incomplete (clinical commentary)